Comparison between six-year therapy with long-acting somatostatin analogs and successful surgery in acromegaly: Effects on cardiovascular risk factors

Journal of Clinical Endocrinology and Metabolism

Volumn 91, Issue 1, 2006, Pages 121-128

  Ronchi, Cristina L ^a,b   Varca, Virginia ^a   Beck Peccoz, Paolo ^a   Orsi, Emanuela ^a   Donadio, Francesca ^a   Baccarelli, Andrea ^a   Giavoli, Claudia ^a   Ferrante, Emanuele ^a   Lania, Andrea ^a   Spada, Anna ^a   Arosio, Maura ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN; SOMATOSTATIN; TRIACYLGLYCEROL;

ACROMEGALY; ADULT; ARTICLE; BLOOD PRESSURE; BODY MASS; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GLUCOSE HOMEOSTASIS; GLUCOSE TOLERANCE; HOMEOSTASIS; HUMAN; INSULIN RELEASE; INSULIN SENSITIVITY; MALE; MEDICAL ASSESSMENT; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; REMISSION; SURGICAL TECHNIQUE;

ACROMEGALY; ADULT; BLOOD GLUCOSE; BODY MASS INDEX; CARDIOVASCULAR DISEASES; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN; INSULIN RESISTANCE; MALE; MIDDLE AGED; NEUROSURGICAL PROCEDURES; RISK FACTORS; SOMATOSTATIN; WAIST-HIP RATIO;

EID: 30344460510     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2005-1704     Document Type: Article

References (48)

1. Melmed S 1990 Acromegaly. N Engl J Med 322:966-977
2. Orme SM, McNally RJ, Cartwright RA, Belchetz PE 1998 Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab 83:2730-2734
3. Holdaway IM, Rajasoorya RC, Gamble GD 2004 Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 89:667-674
4. Clayton RN 2003 Cardiovascular function in acromegaly. Endocr Rev 24:272-277
5. Foss MC, Saad MJA, Paccola GMGF, Paula FJA, Piccinato CE, Moreira AC 1991 Peripheral glucose metabolism in acromegaly. J Clin Endocrinol Metab 72:1048-1053
6. Hansen I, Tsalikian E, Beaufrere B, Gerich J, Haymond M, Rizza R 1986 Insulin resistance in acromegaly: defects in both hepatic and extrahepatic insulin action. Am J Physiol 250:E269-E273
7. Pietrobelli DJ, Akopian M, Olivieri AO, Renauld A, Garrido D, Artese R, Feldstein CA 2001 Altered circadian blood pressure profile in patients with active acromegaly. Relationship with left ventricular mass and hormonal values. J Hum Hypertens 15:601-605
8. Arosio M, Sartore G, Rossi CM, Casati G, Faglia G, Manzato E 2000 LDL physical properties, lipoprotein and Lp(a) levels in acromegalic patients. Effects of octreotide therapy. Italian Multicenter Octreotide Study Group. Atherosclerosis 151:551-557
9. Sartorio A, Cattaneo M, Bucciarelli P, Bottasso B, Porretti S, Epaminonda P, Faglia G, Arosio M 2000 Alterations of haemostatic and fibrinolytic markers in adult patients with growth hormone deficiency and with acromegaly. Exp Clin Endocrinol Diabetes 108:486-492
10. Melmed S, Casanueva FF, Cavagnini F, Chanson P, Frohman L, Grossman A, Ho K, Kleinberg D, Lamberts S, Laws E, Lombardi G, Vance ML, Werder KV, Wass J, Giustina A, Acromegaly Treatment Consensus Workshop Participants 2002 Guidelines for acromegaly management. J Clin Endocrinol Metab 87:4054-4058
11. Jaffrain-Rea ML, Minniti G, Moroni C, Esposito V, Ferretti E, Santoro A, Infusino T, Tamburrano G, Cantore G, Cassone R 2003 Impact of successful transsphenoidal surgery on cardiovascular risk factors in acromegaly. Eur J Endocrinol 148:193-201
12. Swearingen B, Barker Jr FG, Katznelson L, Biller BM, Grinspoon S, Klibanski A, Moayeri N, Black PM, Zervas NT 1998 Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 83:3419-3426
13. James RA, Moller N, Chatterjee S, White M, Kendall-Taylor P 1991 Carbohydrate tolerance and serum lipids in acromegaly before and during treatment with high dose octreotide. Diabet Med 8:517-523
14. Ho KK, Jenkins AB, Furler SM, Borkman M, Chisholm DJ 1992 Impact of octreotide, a long-acting somatostatin analogue, on glucose tolerance and insulin sensitivity in acromegaly. Clin Endocrinol (Oxf) 36:271-279
15. Arosio M, Macchelli S, Rossi CM, Casati G, Biella O, Faglia G 1995 Effects of treatment with octreotide in acromegalic patients - a multicenter Italian study. Eur J Endocrinol 133:922-928
16. Giusti M, Gussoni G, Cuttica CM, Giordano G 1996 Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study. Italian Multicenter Slow Release Lanreotide Study Group. J Clin Endocrinol Metab 81:2089-2097
17. Colao A, Marzullo P, Ferone D, Spinelli L, Cuocolo A, Bonaduce D, Salvatore M, Boerlin V, Lancranjan I, Lombardi G 2000 Cardiovascular effects of depot long-acting somatostatin analog Sandostatin LAR in acromegaly. J Clin Endocrinol Metab 85:3132-3140
18. Ronchi C, Epaminonda P, Cappiello V, Beck-Peccoz P, Arosio M 2002 Effects of two different somatostatin analogs on glucose tolerance in acromegaly. J Endocrinol Invest 25:502-507
19. Ronchi CL, Orsi E, Giavoli C, Cappiello V, Epaminonda P, Beck-Peccoz P, Arosio M 2003 Evaluation of insulin resistance in acromegalic patients before and after treatment with somatostatin analogues. J Endocrinol Invest 26:533-538
20. Baldelli R, Battista C, Leonetti F, Ghiggi MR, Ribaudo MC, Paoloni A, D'Amico E, Ferretti E, Baratta R, Liuzzi A, Trischitta V, Tamburrano G 2003 Glucose homeostasis in acromegaly: effects of long-acting somatostatin analogues treatment. Clin Endocrinol (Oxf) 59:492-499
21. Pereira AM, Biermasz NR, Roelfsema F, Romijn JA 2005 Pharmacologic therapies for acromegaly: a review of their effects on glucose metabolism and insulin resistance. Treat Endocrinol 4:43-53
22. Growth Hormone Research Society; Pituitary Society 2004 Biochemical assessment and long-term monitoring in patients with acromegaly: statement from a Joint Consensus Conference of the Growth Hormone Research Society and the Pituitary Society. J Clin Endocrinol Metab 89:3099-3102
23. Giustina A, Barkan A, Casanueva FF, Cavagnini F, Frohman L, Ho K, Veldhuis J, Wass J, Von Werder K, Melmed S 2000 Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 85:526-529
24. Ronchi CL, Varca V, Giavoli C, Epaminonda, Beck-Peccoz P, Spada A, Arosio M 2005 Long-term evaluation of postoperative acromegalic patients in remission with previous and newly proposed criteria. J Clin Endocrinol Metab 90:1377-1382
25. Epaminonda P, Porretti S, Cappiello V, Faglia G, Arosio M 2001 Efficacy of radiotherapy in normalizing serum IGF-I, acid-labil subunit (ALS) and IGF-BP3 levels in acromegaly. Clin Endocrinol (Oxf) 55:183-189
26. Brehm A, Pfeiler G, Pacini G, Vierhapper H, Roden M 2004 Relationship between serum lipoprotein ratios and insulin resistance in obesity. Clin Chem 50:2316-2322
27. Matthews DR, Hosker JP, Rudeneki AS, Naylor BA, Treacher DF, Turner RC 1985 Homeostasis model assessment insulin resistance and β-cell function from fasting plasma glucose and insulin concentration in man. Diabetologia 28:412-419
28. Katz A, Nambi SS, Mather K 2000 Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 85:2402-2410
29. Matsuda M, DeFronzo RA 1999 Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22:1462-1470
30. Stumvoll M, Mitrakou A, Pimenta W, Jenssen T, Yki-Jarvinen H, Van Haeften T, Renn W, Gerich J 2000 Use of the oral glucose tolerance test to assess insulin release and insulin sensitivity. Diabetes Care 23:295-301
31. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults 2001 Executive summary of the third report of the national cholesterol education program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (ATPIII). JAMA 287:356-359
32. World Health Organization 1999 Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO consultation. I. Diagnosis and classification of diabetes mellitus. Geneva: World Health Organization
33. Jermendy G, Hidvegi T, Hetyesi K, Biro L 2004 Is it time to use the new lower limit of impaired fasting glucose (IFG) among the ATP III criteria for diagnosis of the metabolic syndrome? Prevalence rate of the metabolic syndrome using old and new lower limits of IFG in obese and/or hypertensive subjects. Diabetes Nutr Metab 17:169-170
34. Cozzi R, Attanasio R, Montini M, Pagani G, Lasio G, Lodrini S, Barausse M, Albizzi M, Dallabonzana D, Pedroncelli AM 2003 Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results? J Clin Endocrinol Metab 88:3090-3098
35. Attanasio R, Baldelli R, Pivonello R, Grottoli S, Bocca L, Gasco V, Giusti M, Tamburrano G, Colao A, Cozzi R 2003 Lanreotide 60 mg, a new long-acting formulation: effectiveness in the chronic treatment of acromegaly. J Clin Endocrinol Metab 88:5258-5265
36. Gutt B, Bidlingmaier M, Kretschmar K, Dieterle C, Steffin B, Schopohl J 2005 Four-year follow-up of acromegalic patients treated with the new long-acting formulation of lanreotide (lanreotide Autogel). Exp Clin Endocrinol Diabetes 113:139-144
37. Hopkins KD, Holdaway IM 1992 Insulin secretion and insulin-like growth factor-I levels in active and controlled acromegaly. Clin Endocrinol (Oxf) 36:53-57
38. UK Prospective Diabetes Study (UKPDS) Group 1998 Intensive blood-glucose control sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853
39. Colao A, Baldelli R, Marzullo P, Ferretti F, Ferone D, Gargiulo P, Petretta M, Tamburrano G, Lombardi G, Liuzzi A 2000 Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy. J Clin Endocrinol Metab 85:193-199
40. Bevan JS, Atkin SL, Atkinson AB, Bouloux PM, Hanna F, Harris PE, James RA, McConnell M, Roberts GA, Scanlon MF, Stewart PM, Teasdale E, Turner HE, Wass JA, Wardlaw JM 2002 Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I and tumor size. J Clin Endocrinol Metab 87:4554-4563
41. Wiesli P, Schaffler E, Seifert B, Schmid C, Donath MY 2004 Islets secretory capacity determines glucose homoeostasis in the face of insulin resistance. Swiss Med Wkly 134:559-564
42. Barkan AL, Burman P, Clemmons DR, Drake WM, Gagel RF, Harris PE, Trainer PJ, Van Der Lely AJ, Lee Vance M 2005 Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant. J Clin Endocrinol Metab 90:5684-5691
43. Biermasz NR, Pereira AM, Frolich M, Romijn JA, Veldhuis JD, Roelfsema F 2004 Octreotide represses secretory-burst mass and nonpulsatile secretion but does not restore event frequency or orderly GH secretion in acromegaly. Am J Physiol 286:E25-E30
44. van Thiel SW, Bax JJ, Biermasz NR, Holman ER, Poldermans D, Roelfsema F, Lamb HJ, van der Wall EE, Smit JW, Romijn JA, Pereira AM 2005 Persistent diastolic dysfunction despite successful long-term octreotide treatment in acromegaly. Eur J Endocrinol 153:231-238
45. Kasayama S, Otsuki M, Takagi M 2000 Impaired β-cell function in the presence of reduced insulin sensitivity determines glucose tolerance status in acromegalic patients. Clin Endocrinol (Oxf) 52:549-555
46. Reinehr T, Kiess W, Andler W 2005 Insulin sensitivity indices of glucose and free fatty acid metabolism in obese children and adolescents in relation to serum lipids. Metabolism 54:397-402
47. Bondanelli M, Ambrosio MR, Degli Uberti EC 2001 Pathogenesis and prevalence of hypertension in acromegaly. Pituitary 4:239-249
48. Moller DE, Kaufman KD 2005 Metabolic syndrome: a clinical and molecular perspective. Annu Rev Med 56:45-62